Upgrade to SI Premium - Free Trial

Wolfe Research stays Outperform on Johnson & Johnson (JNJ): focus shifts to upcoming h2h trial data

March 18, 2026 8:43 AM
Wolfe Research analyst Alexandria Hammond reiterated an Outperform rating and $260.00 price target on Johnson & Johnson (NYSE: JNJ)The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments